portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 Daiichi Sankyo receives approval for Silodosin in China
 
CreateTime:2011-09-23 Editor:qulina
Text Size:       
 

Singapore, Sep 22, 2011: Daiichi Sankyo announced that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing), has received approval from China's State Food and Drug Administration (SFDA) for silodosin, which was developed for treatment of dysuria associated with benign prostatic hyperplasia.

By inhibiting the alpha 1A-adrenergic receptor, which exists in the prostate, silodosin relieves the tension in the prostate, lessening pressure and reducing urethral resistance to treat dysuria associated with benign prostatic hyperplasia. Silodosin delivers faster efficacy compared with existing drugs, and can treat symptoms of urinary dysfunction, such as urinary difficulty, and other symptoms, including frequent urination and the sensation of incomplete bladder emptying.


Silodosin is a selective alpha 1A-adrenoceptor antagonist that was originally discovered by Kissei Pharmaceutical. It was developed by Daiichi Sankyo and Kissei Pharmaceutical in Japan and is jointly marketed under the brand name, Urief.
Daiichi Sankyo (Beijing) has the licensing rights for development, manufacture and marketing of silodosin in China. Daiichi Sankyo is committed to contributing to the improvement of quality of life for patients in China while increasing its presence there through the launch of silodosin and other innovative pharmaceuticals.


Related Reports
China Vacuum Blood Collection Device Industry Report, 2019-2025
China Human Vaccine Industry Report, 2019-2025
China Independent Clinical Laboratory Industry Report, 2019-2025
Global and China Monoclonal Antibody Industry Report, 2019-2025
China Contract Research Organization (CRO) Industry Report, 20...
2005-2010 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1